Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray (THC/CBD): Dimension and Possible Causes

CNS Neuroscience and Therapeutics

Volumn 21, Issue 3, 2015, Pages 215-221

  Di Marzo, Vincenzo ^a   Centonze, Diego ^b,c  

^a CNR   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Endocannabinoid system; Multiple sclerosis; Placebo; Spasticity; 9 tetrahydrocannabinol and cannabidiol

Indexed keywords

NABIXIMOLS; PLACEBO; CANNABIDIOL; DRONABINOL; MUSCLE RELAXANT AGENT; ORAL SPRAY;

DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; PLACEBO EFFECT; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPASTICITY; CLINICAL TRIAL (TOPIC); MUSCLE SPASTICITY; ORAL SPRAY; PATHOPHYSIOLOGY; PSYCHOLOGY;

CANNABIDIOL; CLINICAL TRIALS AS TOPIC; DRONABINOL; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; ORAL SPRAYS; PLACEBO EFFECT;

EID: 84923938339     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12358     Document Type: Review

References (42)

1. Moore RA, Derry S, Wiffen PJ. Challenges in design and interpretation of chronic pain trials. Br J Anaesth 2013;111:38-45.
2. Bjørkedal E, Flaten MA. Interaction between expectancies and drug effects: An experimental investigation of placebo analgesia with caffeine as an active placebo. Psychopharmacology 2011;215:537-548.
3. Walach H, Schneider R. Does the presence of a pharmacological substance alter the placebo effect? Results of two experimental studies using the placebo-caffeine paradigm. Hum Psychopharmacol 2009;24:549-558.
4. Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag 2011;16:337-351.
5. ®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-1131.
6. Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012;153:2073-2082.
7. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10:589-595.
8. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage 2004;28:140-175.
9. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;(4):CD001332.
10. Sativex Summary of Product Characteristics 2012. http://www.medicines.org.uk/emc/medicine/23262 (Accessed 14/01/2014).
11. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-4034.
12. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post-hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30:974-985.
13. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:1-8.
14. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-296.
15. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-459.
16. Wade DT, Collin C, Stott C, Dumcombe P. Meta-analysis of the efficacy and safety of Sativex, on spasticity in people with multiple sclerosis. Mult Scler 2010;16:707-714.
17. ® (nabiximols). Mult Scler 2012;18:219-228.
18. ®) in clinical practice - results of a multicentre, non-interventional study (MOVE 2) in patients with Multiple Sclerosis Spasticity (MSS). Eur Neurol 2014;71:173-181.
19. Brown MB, Forsythe AB. Robust tests for equality of variances. J Am Stat Assoc 1974;69:364-367.
20. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805.
21. Pauer L, Winkelmann A. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-2652.
22. McLaughlin RJ. Gobbi. Cannabinoids and emotionality: A neuroanatomical perspective. Neuroscience 2012;204:134-144.
23. Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives. J Psychopharmacol 2012;26:150-163.
24. Weston-Green K, Huang XF, Han M, Deng C. The effects of antipsychotics on the density of cannabinoid receptros in the dorsal vagal complex of rats: Implications for olanzapin-induced weight gain. Int J Neurpsychopharmacol 2008;11:827-835.
25. Micale V, Cristino L. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009;34:593-606.
26. Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neurosychopharmcaology 2006;31:2591-2599.
27. Hill MN, Carrier EJ, McLaughlin RJ, et al. Regional alteration in the endocannabinoid system in an animal model of depression: Effects of concurrent antidepressant treatment. J Neurochem 2008;106:2322-2336.
28. Mato S, Vidal R, Castro E, Díaz A, Pazos A, Valdizán EM. Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol Pharmacol 2010;77:424-434.
29. McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: A systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE 2014;3:e89566.
30. Mitjans M, Gastó C, Catalán R, Fañanás L, Arias B. Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: The role of the CNR1, CNR2 and FAAH genes. J Psychopharmacol 2012;26:1391-1398.
31. Sidhpura N, Parsons LH. Endocannabinoid-mediated synaptic plasticity and addiction-related behaviour. Neuropharmacology 2011;61:1070-1087.
32. Centonze D, Koch G, Versace V, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology 2007;68:1045-1050.
33. Krishnan RV. Botulinum toxin: From spasticity reliever to a neuromotor re-learning tool. Int J Neurosci 2005;115:1451-1467.
34. Kumru H, Kofler M. Effect of spinal cord injury and of intrathecal baclofen on brainstem reflexes. Clin Neurophysiol 2012;123:45-53.
35. Mori F, Codecà C, Kusayanagi H, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol 2010;17:295-300.
36. Koch G, Mori F, Codecà C, et al. Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans. Brain Stimul 2009;2:229-233.
37. Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiol Dis 2013;59:141-150.
38. Centonze D, Bari M, Rossi S, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007;130:2543-2553.
39. Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med 2011;17:1228-1230.
40. Peciña M, Martínez-Jauand M, Hodgkinson C, Stohler CS, Goldman D, Zubieta JK. FAAH selectively influences placebo effects. Mol Psychiatry 2014;19:385-391.
41. Vlachou S, Panagis G. Regulation of Brain Reward by the Endocannabinoid System: A critical Review of Behavioral Studies in Animals. Curr Pharm Des 2014;20:2072-2088.
42. Rossi S, Bozzali M, Bari M, et al. Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis. PLoS ONE 2013;8:e82848.